HTF Market Intelligence released a new research report of 157 pages on title ‘Dyskinesia – Pipeline Review, H1 2017’ with detailed analysis, forecast and strategies. The study covers key regions and important players such as EpiVax Inc, Heptares Therapeutics Ltd, Ipsen SA etc.
Request a sample report @ https://www.htfmarketreport.com/sample-report/437115-dyskinesia-pipeline-review
The latest Pharmaceutical and Healthcare disease pipeline guide Dyskinesia – Pipeline Review, H1 2017, provides an overview of the Dyskinesia (Central Nervous System) pipeline landscape.
Dyskinesia refers to the involuntary nature of muscular movements or the difficulty in performing voluntary muscular movement. Symptoms include facial grimacing, finger movement, jaw swinging, repetitive chewing and tongue thrusting. The disease can be controlled by healthy life style and medication.
The Pharmaceutical and Healthcare latest pipeline guide Dyskinesia – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Dyskinesia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Dyskinesia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 11, 6, 18 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.
Dyskinesia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=437115
– The pipeline guide provides a snapshot of the global therapeutic landscape of Dyskinesia (Central Nervous System).
– The pipeline guide reviews pipeline therapeutics for Dyskinesia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Dyskinesia (Central Nervous System) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Dyskinesia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Dyskinesia (Central Nervous System)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Dyskinesia (Central Nervous System).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Dyskinesia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned in the Report
Adamas Pharmaceuticals Inc
Addex Therapeutics Ltd
Astraea Therapeutics LLC
Avanir Pharmaceuticals Inc
Catalyst Biosciences Inc
Catalyst Pharmaceuticals Inc
Clevexel Pharma SAS
Heptares Therapeutics Ltd
Merz Pharma GmbH & Co KgaA
Neurim Pharmaceuticals Ltd
Neurocrine Biosciences Inc
Osmotica Pharmaceutical Corp
Phenomenome Discoveries Inc
Sage Therapeutics Inc
SciFluor Life Sciences LLC
SOM Biotech SL
Teva Pharmaceutical Industries Ltd
Make an enquiry before buying this Report @ https://www.htfmarketreport.com/enquiry-before-buy/437115-dyskinesia-pipeline-review
Table of Contents
List of Tables 5
List of Figures 6
The Report Coverage 7
Dyskinesia – Overview 8
Dyskinesia – Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 13
Products under Development by Companies 14
Products under Development by Universities/Institutes 17
Dyskinesia – Therapeutics Assessment 18
Assessment by Target 18
Assessment by Mechanism of Action 21
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Dyskinesia – Companies Involved in Therapeutics Development 28
Adamas Pharmaceuticals Inc 28
Addex Therapeutics Ltd 28
Advicenne SA 29
Astraea Therapeutics LLC 29
Avanir Pharmaceuticals Inc 30
Bionomics Ltd 30
Catalyst Biosciences Inc 31
Catalyst Pharmaceuticals Inc 31
Cavion LLC 32
Clevexel Pharma SAS 32
EpiVax Inc 33
Heptares Therapeutics Ltd 33
Ipsen SA 34
Merz Pharma GmbH & Co KgaA 34
Neurim Pharmaceuticals Ltd 35
Neurocrine Biosciences Inc 35
Neurolixis Inc 36
Osmotica Pharmaceutical Corp 36
Phenomenome Discoveries Inc 37
Sage Therapeutics Inc 37
SciFluor Life Sciences LLC 38
SOM Biotech SL 38
Synchroneuron Inc 39
Teva Pharmaceutical Industries Ltd 39
Dyskinesia – Drug Profiles 40
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/437115-dyskinesia-pipeline-review
CRAIG FRANCIS (PR & Marketing Manager)
Ph: +1 (206) 317 1218